To this end, cell-type-specific effects of PGE2 may take place during the different stages of MS pathology, which may explain why solely silencing EP2 may not yield significant beneficial effects during EAE onset, as EP4 signalling on Th17 lymphocytes can still contribute to the pro-inflammatory CNS environment at this stage. The gene discussed is PTGER4; the disease is myeloid sarcoma.